In a randomized, placebo-controlled trial of 80 participants, a single lonvo-z infusion reduced HAE attack frequency during the prespecified follow-up window. The abstract reports infusion-related and other adverse events; it does not establish lifelong safety or an FDA outcome.
Program relevance
Phase 3 HAELO (NCT06634420) studies lonvo-z in hereditary angioedema, matching the catalog program.
Formulation / population: Single-dose intravenous lonvo-z in HAE with C1-inhibitor deficiency.
Journal Article / Randomized Controlled Trial / Clinical Trial, Phase III / Multicenter Study
A small randomized phase 2 study compared two single NTLA-2002 doses with placebo. Treated groups had fewer HAE attacks and reduced plasma kallikrein; the authors supported further phase 3 investigation.
Program relevance
Earlier NTLA-2002 phase 1/2 program (NCT05120830) in hereditary angioedema; this is not the later HAELO cohort.
Formulation / population: Single intravenous NTLA-2002 doses of 25 or 50 mg in adults with HAE.
Earlier phase 1/2 program; different cohort and follow-up from HAELO.
Clinical Trial, Phase II / Journal Article / Multicenter Study / Randomized Controlled Trial